Metfogamma

Metformin Hydrochloride, the active ingredient in Metfogamma, is a biguanide presented as an oral dosage form for oral use. It is used to improve blood glucose control in adults with type 2 diabetes and is also employed off‑label for polycystic ovary syndrome.

GNH USA supplies Metfogamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metfogamma belongs to the biguanide class and is used to manage disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels, helping achieve glycaemic targets. - Polycystic ovary syndrome (off‑label): improves insulin resistance, which can restore ovulatory cycles and reduce androgen levels. - Prediabetes: delays progression to overt diabetes by improving insulin sensitivity and reducing hepatic glucose output.

Metfogamma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate, particularly in patients with renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: abnormal liver enzymes indicating potential liver injury. - Vitamin B12 deficiency: may develop with long‑term therapy, leading to anemia. - Hypoglycaemia: uncommon when used alone but possible when combined with other glucose‑lowering agents.

Before initiating Metfogamma, several safety considerations should be reviewed. - Renal function assessment: ensure adequate kidney function to avoid accumulation and lactic acidosis. - Hepatic function monitoring: evaluate liver enzymes, as impaired function can increase risk of adverse events. - Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: classified as Category B; use only if benefits outweigh potential risks. - Vitamin B12 monitoring: periodic testing recommended during long‑term therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metfogamma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging. - Cimetidine: may raise metformin plasma concentrations, enhancing toxicity. - Alcohol: excessive intake can potentiate lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors and diuretics: can affect renal function, requiring dose adjustment. - Warfarin: may increase INR, necessitating closer coagulation monitoring.